Get the Stockscreener App
1.34
2.29%
0.03
After Hours:
1.33
-0.01
-0.75%
Durect Corp stock is traded at $1.34, with a volume of 57,096.
It is up +2.29% in the last 24 hours and down -9.46% over the past month.
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the Europe .
See More
Previous Close:
$1.31
Open:
$1.29
24h Volume:
57,096
Relative Volume:
0.76
Market Cap:
$40.66M
Revenue:
$9.19M
Net Income/Loss:
$-36.65M
P/E Ratio:
-0.8701
EPS:
-1.54
Net Cash Flow:
$-34.57M
1W Performance:
+5.51%
1M Performance:
-9.46%
6M Performance:
+10.74%
1Y Performance:
-46.18%
1-Day Range:
$1.28
$1.34
1-Week Range:
$1.15
$1.3652
52-Week Range:
$0.4703
$3.14
Durect Corp Stock (DRRX) Company Profile
Name
Durect Corp
Sector
Phone
(408) 777-1417
Address
10240 BUBB ROAD, CUPERTINO, CA
Durect Corp Stock (DRRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-30-20 | Initiated | Chardan Capital Markets | Buy |
| Oct-12-20 | Initiated | ROTH Capital | Buy |
| Jul-31-20 | Initiated | Oppenheimer | Outperform |
| Jan-31-20 | Initiated | B. Riley FBR | Buy |
| Nov-18-19 | Resumed | Cantor Fitzgerald | Overweight |
| Sep-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-06-18 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-20-17 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Oct-20-17 | Reiterated | Laidlaw | Buy |
| Oct-20-17 | Downgrade | Stifel | Buy → Hold |
| Jul-12-17 | Upgrade | Stifel | Hold → Buy |
| Feb-28-17 | Resumed | H.C. Wainwright | Buy |
| Apr-25-16 | Initiated | Rodman & Renshaw | Buy |
| May-01-15 | Reiterated | Cantor Fitzgerald | Buy |
| May-01-15 | Reiterated | Stifel | Buy |
| Mar-25-13 | Initiated | Stifel | Buy |
| Nov-01-12 | Downgrade | C.K. Cooper | Buy → Hold |
| Aug-17-12 | Initiated | C.K. Cooper | Buy |
| Jun-23-09 | Initiated | Caris & Company | Buy |
| Mar-26-09 | Initiated | Wedbush Morgan | Hold |
View All
Durect Corp Stock (DRRX) Latest News
Durect Corp Annual Meeting Decisions and Shareholder Votes - TipRanks
H.C. Wainwright maintains Neutral rating on Durect shares post FDA meeting - Investing.com
DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis - StockTitan
DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference - PR Newswire
Durect Corp (NQ: DRRX - Financial Content
Durect (FRA:DC8A) Total Inventories : €2.30 Mil (As of Jun. 2024) - GuruFocus.com
DURECT Co. (NASDAQ:DRRX) Expected to Post Q3 2024 Earnings of ($0.14) Per Share - Defense World
HC Wainwright Analysts Reduce Earnings Estimates for DURECT Co. (NASDAQ:DRRX) - Defense World
DURECT Corporation (NASDAQ:DRRX) Q2 2024 Earnings Call Transcript - Insider Monkey
Earnings call: DURECT Corp reports steady Q2 financials, plans Phase III trial - Investing.com India
Earnings call: DURECT Corp reports steady Q2 financials, plans Phase III trial - Investing.com
Durect: Q2 Earnings Snapshot - Houston Chronicle
Durect (DRRX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Durect: Q2 Earnings Snapshot - Barchart
DURECT Corporation Reports Second Quarter 2024 Financial Results and Business Update - PR Newswire
DURECT (DRRX) Set to Announce Quarterly Earnings on Tuesday - Defense World
DURECT Co. (NASDAQ:DRRX) Receives $27.50 Average Target Price from Brokerages - American Banking and Market News
DURECT Corporation to Announce Second Quarter 2024 Financial Results and Provide a Business Update - StockTitan
ProAssurance Co. (NYSE:PRA) Shares Bought by CANADA LIFE ASSURANCE Co - Defense World
DURECT (DRRX) Stock Price, News & Analysis - MarketBeat
Altair Engineering (NASDAQ:ALTR) Stock Rating Lowered by The Goldman Sachs Group - Defense World
DURECT (NASDAQ:DRRX) Stock Price Passes Above Two Hundred Day Moving Average of $1.13 - MarketBeat
DURECT Co. (NASDAQ:DRRX) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
DURECT (NASDAQ:DRRX) Stock Price Passes Above 200-Day Moving Average of $1.01 - Defense World
Durect - The Pharma Letter
DURECT Corporation Announces Presentations in Upcoming Investor Conferences - Quantisnow
DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update - Quantisnow
DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update - Quantisnow
DURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - Quantisnow
DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol ... - Quantisnow
DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update - Quantisnow
Are Medical Stocks Lagging DURECT (DRRX) This Year? - Yahoo Canada Finance
Short Interest in DURECT Co. (NASDAQ:DRRX) Increases By 15.1% - MarketBeat
DURECT Co. (NASDAQ:DRRX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
DURECT Co. (NASDAQ:DRRX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Drug ManufacturersOther Equities Technical Momentum -- DepoMed, Pernix Therapeutics Holdings, Novo Nordisk ... - br.ADVFN.com
DURECT Corporation Announces Update on DUR-928 Development Program - br.ADVFN.com
Financial Metrics Exploration: Understanding Durect Corp (DRRX) Through Ratios – DWinneX - The Dwinnex
DURECT (NASDAQ:DRRX) Stock Crosses Above Two Hundred Day Moving Average of $0.86 - Defense World
Durect Corp’s Mixed Bag: Up 110.54% in 6 Months, Up 60.25% in 30 Days - The InvestChronicle
Durect stock eyes by H.C Wainwright despite FDA's breakthrough drug designation - Investing.com
FDA grants Breakthrough Therapy status for DURECT's larsucosterol - Investing.com
DURECT gets FDA breakthrough therapy status for larsucosterol (NASDAQ:DRRX) - Seeking Alpha
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated ... - Yahoo Finance
Hope for people with severe alcohol-associated hepatitis thanks to epigenetic therapy - OutSourcing-Pharma.com
U.S. shares mixed at close of trade; Dow Jones Industrial Average down 0.12% - MSN
U.S. stocks mixed at close of trade; Dow Jones Industrial Average down 0.12% - MSN
Q2 2024 EPS Estimates for DURECT Co. Lifted by Analyst (NASDAQ:DRRX) - Defense World
DURECT Co. to Post FY2024 Earnings of ($0.90) Per Share, Northland Capmk Forecasts (NASDAQ:DRRX) - Defense World
Brokers Set Expectations for DURECT Co.'s Q2 2024 Earnings (NASDAQ:DRRX) - Defense World
Disclosure of trading in own shares from May 2nd to May 8th, 2024 - Yahoo Finance Australia
Durect Corp Stock (DRRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.23%
0.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):